Delini-Stula Alexandra, Bondolfi Guido, Holsboer-Trachsler Edith
ADI International Institute for Advancement of Drug Development GmbH, Bâle.
Rev Med Suisse. 2010 Jun 30;6(255):1370-4.
Among a variety of drugs used in the treatment of anxiety disorders, benzodiazepines and antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are at present the most established and prescribed. In fact, recent guidelines recommend the antidepressants SSRI and SNRI as well as pregabaline, a newly developed drug, as the 1st choice treatment in generalized anxiety disorder (GAD). However, antidepressants have several disadvantages (latency of onset of action, adverse effects and drug interactions) that should not be neglected. Pregabaline is a drug with a new mechanism of action. Clinical studies up to now indicate a rather rapid and efficient anxiolytic effect comparable to that of benzodiazepines, with no risk of abuse. Pregabaline has been recently introduced in Switzerland for the treatment of GAD.
在用于治疗焦虑症的多种药物中，苯二氮䓬类药物以及抗抑郁药，如选择性5-羟色胺再摄取抑制剂（SSRI）和5-羟色胺与去甲肾上腺素再摄取抑制剂（SNRI），是目前最常用且处方量最大的药物。事实上，近期的指南推荐抗抑郁药SSRI和SNRI以及新开发的药物普瑞巴林，作为广泛性焦虑症（GAD）的首选治疗药物。然而，抗抑郁药存在一些不容忽视的缺点（起效延迟、副作用和药物相互作用）。普瑞巴林是一种作用机制新颖的药物。迄今为止的临床研究表明，其抗焦虑作用相当迅速且有效，与苯二氮䓬类药物相当，且无滥用风险。普瑞巴林最近已在瑞士被用于治疗广泛性焦虑症。
